Total Testosterone Longevity-Medicine Target Ranges

What Is Total Testosterone and Why Does It Matter for Longevity?

Total testosterone measures all circulating testosterone: the fraction bound to sex hormone-binding globulin (SHBG), the fraction loosely bound to albumin, and the small free fraction. Together these pools govern muscle protein synthesis, erythropoiesis, bone mineral density, libido, mood, and metabolic rate. Low total testosterone in men associates independently with all-cause mortality, cardiovascular events, and insulin resistance in observational data spanning decades.

The European Male Ageing Study (N=3,369) found that men with total testosterone below 317 ng/dL had a hazard ratio of 1.35 for all-cause mortality over 4.3 years compared with men in the upper tertile (P<0.001) [1]. That single datum reframes testosterone from a "vitality" marker into a genuine longevity signal worth tracking serially, not just once at symptom onset.

Why Longevity Practitioners Set Higher Targets Than Standard Labs

Standard laboratory reference ranges are derived from population distributions, not from outcomes data. A value flagged "normal" at 305 ng/dL is normal relative to an aging, often overweight Western population. Longevity-medicine frameworks compare against the testosterone concentrations associated with the lowest all-cause mortality risk, and those concentrations tend to cluster in the upper third of the youthful adult distribution, approximately 600 to 1,000 ng/dL [2].

The Difference Between a Reference Range and an Optimal Target

A reference range says "you are not in the bottom 2.5% of the population." An optimal target says "you are in the zone associated with the best long-term outcomes." These are not the same thing. The Endocrine Society's 2018 guideline defines biochemical hypogonadism at a total testosterone below 300 ng/dL on two morning draws [3], but the same guideline acknowledges that "there is no universally accepted definition of an optimal testosterone level", a direct quotation the longevity field treats as an open invitation to look at outcomes data rather than lab-flag thresholds.

How to Measure Total Testosterone Accurately

Accurate measurement is not automatic. Draw timing, assay method, and patient preparation each introduce meaningful variance.

Draw Timing

Testosterone follows a circadian rhythm with peak concentrations between 7:00 AM and 10:00 AM. A draw at 2:00 PM can read 25 to 30% lower than an 8:00 AM draw in the same individual [4]. The Endocrine Society and the American Urological Association both specify a morning draw for diagnostic purposes [3, 5].

Assay Method: LC-MS/MS vs. Immunoassay

Immunoassay platforms (the most common method at commercial labs) show inter-assay coefficients of variation above 15% at low concentrations. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) reduces that to under 5% and removes cross-reactivity with adrenal androgens [6]. The CDC Hormone Standardization Program (HoSt) certifies reference labs using LC-MS/MS; when precision matters for serial monitoring, use a HoSt-certified assay [7].

Fasting and Acute Illness

Acute illness, sleep deprivation of even one night, and a high-carbohydrate meal each suppress testosterone transiently by 10 to 15% [8]. Fasting overnight before a morning draw removes one variable. Rescheduling the draw after recovery from acute illness removes another.

Confirming a Low Result

Before initiating TRT, obtain two separate morning fasting values on different days. A single low value has a false-positive rate of roughly 30% due to episodic pulsatile secretion [3]. Confirming the result protects against unnecessary treatment.

Standard Clinical Reference Ranges

Most US laboratories report total testosterone in adult men using a range of roughly 264 to 916 ng/dL, derived from the 2011 Endocrine Society/CDC reference population of healthy non-obese men aged 19 to 39 [9]. Values below 300 ng/dL on two morning draws meet the Endocrine Society biochemical criterion for hypogonadism [3].

For women, the clinical reference range is approximately 15 to 70 ng/dL, with premenopausal women typically in the 20 to 60 ng/dL range. The Global Consensus Position Statement on the use of testosterone therapy for women (published in the Journal of Clinical Endocrinology and Metabolism) recommends against pharmacological supraphysiological dosing in women, targeting concentrations within the upper normal premenopausal range [10].

Age-Stratified Ranges in Men

| Age Group | Approximate Population Mean (ng/dL) | Endocrine Society "Low" Threshold | |-----------|--------------------------------------|----------------------------------| | 20 to 29 | 630 | <300 | | 30 to 39 | 580 | <300 | | 40 to 49 | 520 | <300 | | 50 to 59 | 470 | <300 | | 60 to 69 | 410 | <300 | | 70+ | 350 | <300 |

Data extrapolated from the Boston Area Community Health (BACH) Survey and the European Male Ageing Study [1, 11]. These are population medians, not optimal targets.

The SHBG Caveat

Total testosterone can mislead when SHBG is abnormal. Obesity, insulin resistance, hypothyroidism, and exogenous androgen use all suppress SHBG, inflating the free fraction relative to total. Cirrhosis, hyperthyroidism, and aging all raise SHBG, lowering the free fraction even when total testosterone reads normal. In any man with total testosterone between 300 to 400 ng/dL, calculate free testosterone using the Vermeulen equation or measure it by equilibrium dialysis [3].

Longevity-Medicine Target Ranges: The Evidence Base

The shift from "not deficient" to "optimized" is driven by a body of prospective cohort data linking mid-to-high normal testosterone with better metabolic, cardiovascular, and cognitive outcomes.

Cardiovascular Outcomes

A meta-analysis of 11 prospective cohort studies (combined N=11,261) published in the European Heart Journal found that men in the lowest testosterone tertile had a 25% higher risk of cardiovascular events than men in the highest tertile over a median follow-up of 9.7 years [12]. The relationship was roughly linear up to approximately 900 ng/dL, with no significant additional benefit above that concentration.

The Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials in men aged 65 and older with total testosterone below 275 ng/dL (N=788), showed that testosterone treatment for one year increased coronary artery plaque volume on CT angiography compared with placebo [13]. That finding has generated ongoing debate, but it underlines why "optimize to 600 to 1,000 ng/dL" is not the same as "push as high as possible." Supraphysiological levels carry their own risk profile, including erythrocytosis, lipid changes, and cardiovascular strain.

Bone Mineral Density

The TTrials Bone Trial sub-study (N=211) demonstrated that one year of testosterone treatment in hypogonadal men increased volumetric bone mineral density at the lumbar spine by 7.5% vs. 0.8% in placebo (P<0.001) [14]. Bone density is a direct longevity metric: hip fracture in men over 70 carries a one-year mortality of 20 to 30% [15].

Metabolic and Body Composition Effects

The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, randomized middle-aged and older men with hypogonadism and high cardiovascular risk to testosterone gel or placebo for a median 33 months [16]. Testosterone treatment reduced the incidence of new-onset type 2 diabetes by 12% (HR 0.88; 95% CI 0.75 to 1.02), a signal consistent with testosterone's role in glucose uptake and insulin receptor signaling, though the confidence interval crossed 1.0. Lean body mass increased by approximately 1.5 kg and fat mass decreased by approximately 1.0 kg vs. Placebo.

Cognitive Function

A 2023 analysis of the UK Biobank (N=179,000+) found that men in the lowest quartile of total testosterone had a 14% higher risk of incident dementia over 12 years compared with men in the second-highest quartile, after adjustment for BMI, smoking, and comorbidities [17]. The relationship between testosterone and cognitive aging is not settled, but the signal is consistent enough that longevity practitioners include testosterone optimization as one component of a cognitive-preservation strategy.

The 600 to 1,000 ng/dL Longevity Target: Rationale and Limits

Based on the outcomes data above, many longevity-medicine clinicians target total testosterone in the 600 to 1,000 ng/dL range for adult men. The lower bound of 600 ng/dL roughly corresponds to the population median for healthy men in their late 20s, when testosterone-associated morbidity and mortality risk appears lowest. The upper bound of 1,000 ng/dL corresponds to the approximate 97.5th percentile of the youthful reference population and the threshold above which erythrocytosis risk rises meaningfully.

This is not an FDA-approved target. It is a clinical framework derived from cohort data, mechanistic physiology, and the practical experience of practitioners trained in the American Academy of Anti-Aging Medicine and similar longevity medicine bodies. Patients should understand the distinction between population-outcome associations and a randomized controlled trial showing that hitting 800 ng/dL specifically extends lifespan.

TRT Monitoring Protocols and Lab Frequency

Starting TRT without a monitoring plan is poor practice. The Endocrine Society recommends checking total testosterone 3 months after dose initiation or adjustment, then every 6 to 12 months once stable [3].

What to Check Alongside Total Testosterone

Total testosterone alone is insufficient for safe TRT monitoring. A complete androgen panel includes:

• Free testosterone (by equilibrium dialysis or Vermeulen calculation)
• SHBG
• Estradiol (LC-MS/MS sensitive assay, target 20 to 40 pg/mL on TRT)
• Complete blood count (hematocrit; hold or reduce dose if hematocrit exceeds 54%) [3]
• PSA (men over 40; baseline and at 3 to 6 months)
• Lipid panel and fasting glucose

Target Ranges During TRT

On testosterone cypionate 100 mg/week IM or SubQ, most men achieve total testosterone of 600 to 900 ng/dL at the 48 to 72 hour post-injection trough. Peak levels at 24 to 36 hours post-injection may read 200 to 300 ng/dL higher. Standardizing draw timing to the trough (just before the next injection) removes peak-versus-trough variability and gives a reproducible monitoring value [5].

Dose Adjustment Logic

If trough total testosterone reads below 500 ng/dL and symptoms persist, an increase of 10 to 20 mg/week is reasonable. If trough reads above 1,100 ng/dL, reduce dose before the next scheduled visit, values above that level do not add documented benefit and increase erythrocytosis risk. Recheck total testosterone and hematocrit 6 weeks after any dose change [3].

Total Testosterone in Women: Clinical and Longevity Considerations

Women produce testosterone in the ovaries and adrenal glands. Concentrations peak in the mid-20s and decline about 50% by menopause [18]. Low testosterone in women associates with reduced libido, fatigue, decreased muscle mass, and decreased bone density, though the evidence base is far smaller than in men.

Clinical Threshold vs. Longevity Target in Women

The 2019 Global Consensus Position Statement (endorsed by the Endocrine Society, the British Menopause Society, and 10 other societies) supports testosterone therapy for hypoactive sexual desire disorder in postmenopausal women [10]. The recommended target is the upper end of the normal premenopausal range, approximately 40 to 70 ng/dL, with no evidence supporting supraphysiological dosing.

Longevity-medicine data on testosterone targets in women are limited. Observational studies suggest that women in the lower quartile of total testosterone have higher rates of frailty and hip fracture, but no large RCT has established a specific optimal range for longevity endpoints [19].

Measurement Challenges in Women

At concentrations below 50 ng/dL, immunoassay performance is poor. LC-MS/MS is strongly preferred for women's testosterone measurement and is the only method endorsed by the Global Consensus Position Statement for monitoring testosterone therapy in women [10].

Interpreting an Abnormal Total Testosterone Result

A low total testosterone does not automatically mean primary hypogonadism requiring TRT. The differential is broad.

Secondary (Central) Causes

Elevated prolactin, pituitary adenoma, chronic opioid use, anabolic steroid history, severe caloric restriction, and obstructive sleep apnea all suppress the hypothalamic-pituitary-gonadal axis and lower testosterone without any intrinsic testicular pathology [3]. Checking LH and FSH distinguishes primary from secondary hypogonadism: low testosterone with low-normal LH/FSH points to the pituitary or hypothalamus; low testosterone with elevated LH/FSH points to testicular failure.

Reversible Causes to Address First

Before prescribing TRT, address sleep apnea, obesity, and medication-induced suppression. Weight loss of 10% body weight in obese men raises total testosterone by approximately 50 to 100 ng/dL [20]. Treating moderate OSA with CPAP raises total testosterone by a mean 73 ng/dL in men with baseline values below 400 ng/dL, per a 2021 meta-analysis (N=232) [21].

When to Refer

Men with total testosterone below 150 ng/dL, markedly elevated LH/FSH, or palpable testicular abnormality warrant urology or endocrinology referral before TRT initiation. Testosterone below 150 ng/dL may indicate Klinefelter syndrome, prior gonadotoxic therapy, or an undiagnosed pituitary mass [3].

How HealthRX Uses Total Testosterone in the Clinical Workflow

At HealthRX, every new patient presenting for hormone evaluation receives a morning fasting total testosterone by LC-MS/MS, paired with free testosterone (equilibrium dialysis), SHBG, LH, FSH, estradiol, CBC, and metabolic panel. This panel is drawn before any prescription is written.

The longevity target range of 600 to 1,000 ng/dL guides initial dosing decisions. Patients outside that range after 12 weeks of therapy have their dose adjusted, and trough labs are rechecked 6 weeks after each change. The frequency of monitoring visits decreases to every 6 months once the patient achieves two consecutive trough values within the target range.

Patients are counseled explicitly that the longevity-medicine target range is derived from observational outcomes data, not from a randomized trial that titrated testosterone to 800 ng/dL and measured 10-year mortality. That distinction matters for informed consent.